| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,940,000 |
| Market
Cap: |
202.02(M) |
| Last
Volume: |
38,851 |
Avg
Vol: |
19,828 |
| 52
Week Range: |
$1.63 - $1.63 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, the U.S., and throughout the world.. In China, Co.'s first commercial product, EVOMELA® is approved for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The other core hematology/oncology assets in our pipeline include: CNCT19, which is being developed as a potential treatment for patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
371,517 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,315,104 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
11 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tarnow Michael M |
Director |
– • – |
2006-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
35,663 |
|
- |
|
| Knight Peter S |
Director |
– • – |
2006-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
40,216 |
|
- |
|
| Randall Mark C M |
Director |
– • – |
2006-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
40,216 |
|
- |
|
| Burns James S |
President and CEO |
• • – |
2006-06-12 |
4 |
B |
$1.58 |
$7,900 |
D/D |
5,000 |
70,000 |
2.81 |
- |
|
| Bush Dwight L |
Director |
– • – |
2005-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,064 |
24,191 |
|
- |
|
| Tarnow Michael M |
Director |
– • – |
2005-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,064 |
24,191 |
|
- |
|
| Hunter Cevera Jennie |
Director |
– • – |
2005-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,064 |
24,191 |
|
- |
|
| Randall Mark C M |
Director |
– • – |
2005-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,064 |
24,191 |
|
- |
|
| Brooks Donald S |
Director |
– • – |
2005-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,064 |
24,191 |
|
- |
|
| Knight Peter S |
Director |
– • – |
2005-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,064 |
24,191 |
|
- |
|
| Cape Ronald |
Director |
– • – |
2005-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,064 |
24,191 |
|
- |
|
| Burns James S |
President and CEO |
• – – |
2005-04-06 |
4 |
B |
$2.35 |
$35,595 |
D/D |
15,000 |
65,000 |
2.74 |
- |
|
| Celgene Corp /de/ |
10% Owner |
– – • |
2005-03-31 |
4 |
OE |
$1.50 |
$10,500,000 |
D/D |
7,000,000 |
23,750,000 |
|
- |
|
| Burns James S |
President and CEO |
• – – |
2005-01-10 |
4/A |
B |
$3.68 |
$1,840 |
D/D |
500 |
50,000 |
2.66 |
- |
|
| Burns James S |
President and CEO |
• – – |
2005-01-10 |
4 |
B |
$3.63 |
$52,907 |
D/D |
14,500 |
49,500 |
2.74 |
- |
|
| Burns James S |
President and CEO |
• – – |
2004-09-24 |
4 |
B |
$1.66 |
$16,944 |
D/D |
10,000 |
35,000 |
2.74 |
- |
|
| Klein Udo |
Senior Vice President of R&D |
• – – |
2004-09-03 |
4 |
B |
$1.49 |
$2,682 |
D/D |
1,800 |
1,800 |
2.66 |
- |
|
| Sidor Carolyn F |
Corp. VP and Chief Med. OfcrOf |
• – – |
2004-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
- |
|
| Burns James S |
President and CEO |
• – – |
2004-07-14 |
4 |
B |
$1.92 |
$49,118 |
D/D |
25,000 |
25,000 |
2.74 |
- |
|
| Saglio Dane R |
Chief Financial Officer |
• – – |
2004-07-14 |
4 |
A |
$1.95 |
$3,900 |
D/D |
2,000 |
2,300 |
|
- |
|
| Bush Dwight L |
Director |
– • – |
2004-06-16 |
4 |
A |
$2.16 |
$25,000 |
D/D |
11,574 |
16,127 |
|
- |
|
| Tarnow Michael M |
Director |
– • – |
2004-06-16 |
4 |
A |
$2.16 |
$25,000 |
D/D |
11,574 |
16,127 |
|
- |
|
| Hunter Cevera Jennie |
Director |
– • – |
2004-06-16 |
4 |
A |
$2.16 |
$25,000 |
D/D |
11,574 |
16,127 |
|
- |
|
| Cape Ronald |
Director |
– • – |
2004-06-16 |
4 |
A |
$2.16 |
$25,000 |
D/D |
11,574 |
16,127 |
|
- |
|
| Randall Mark C M |
Director |
– • – |
2004-06-16 |
4 |
A |
$2.16 |
$25,000 |
D/D |
11,574 |
16,127 |
|
- |
|
159 Records found
|
|
Page 6 of 7 |
|
|
